Mass General Brigham
Health Plan

Lumvoa (veligrotug-vvze)
Effective 01/04/2027

Plan	☒ MassHealth UPPL ☐Commercial/Exchange	**Program Type**	☒ Prior Authorization ☐ Quantity Limit ☐ Step Therapy
Benefit	☐ Pharmacy Benefit ☒ Medical Benefit		
Specialty Limitations	N/A		
Contact Information	**Medical Benefit** **Pharmacy Benefit**	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions	Lumvoa (veligrotug-vvze) is also available on the pharmacy benefit. Please see the MassHealth Drug List for coverage and criteria.		

Overview
Lumvoa (veligrotug-vvze) is indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration.

Coverage Guidelines
If member is new to the plan (as evidenced by coverage effective date of less than or equal to 90 days), submission of medical records documenting that the member is currently receiving treatment with the requested drug, excluding when the product is obtained as samples or via manufacturer's patient assistance programs
OR
Authorization may be granted when all of the following criteria are met:

1. Diagnosis of thyroid eye disease
2. Member is ≥ 18 years of age
3. Prescriber is an endocrinologist or ophthalmologist, or consult notes from an endocrinologist or ophthalmologist are provided
4. Inadequate response, adverse reaction, or contraindication to glucocorticoids
5. No history of treatment with Tepezza
6. Appropriate dosing

Continuation of Therapy
Reauthorization by physician may be granted for members who have not completed 4 months (5 infusions) of treatment. Additional courses of therapy beyond the initial course will be evaluated on a case-by-case basis to determine medical necessity of repeat treatment, considering severity of disease, response to prior courses of therapy, adherence to prior courses, failed alternative trials, etc.

Limitations
Approvals will be granted for a maximum of 5 infusions (4 months) for one course of therapy per lifetime.

References

1. Lumvoa® [package insert]. Waltham (MA): Viridian Therapeutics, Inc., 2026 June.

2. FDA Approves Lumvoa for Thyroid Eye Disease Across Activity Stages; 2026 Jun 29 [cited 2026 Jul]. Available from: https://www.biopharminternational.com/view/fda-approves-lumvoa-thyroid-eye-disease
3. Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, et al. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. Thyroid. 2022 Dec;32(12):1439-1470. doi: 10.1089/thy.2022.0251. Epub 2022 Dec 8. PMID: 36480280; PMCID: PMC9807259.

Review History

11/4/26 – Created for P&T. Lumvoa injection will be added to both the pharmacy benefit and medical benefit with a prior authorization requirement. A step-through trial requirement for glucocorticoids and confirmation of no historical treatment with Tepezza were included. Effective 1/4/27